World's Best Scientists 2026 revealed!
Toshiaki A. Furukawa

Toshiaki A. Furukawa

Award Badge
Psychology
Japan
2026

D-Index & Metrics

Psychology

D-Index
51
Citations
11929
World Ranking
5175
National Ranking
8

Toshiaki A. Furukawa publication distribution in Psychology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Psychology in 2026. The highlighted bar marks where Toshiaki A. Furukawa sits on this spectrum.

31–40 publications: 6 scientists 41–50 publications: 52 scientists 51–60 publications: 138 scientists 61–70 publications: 299 scientists 71–80 publications: 461 scientists 81–90 publications: 605 scientists 91–100 publications: 713 scientists 101–110 publications: 736 scientists 111–120 publications: 686 scientists 121–130 publications: 670 scientists 131–140 publications: 644 scientists 141–150 publications: 597 scientists 151–160 publications: 576 scientists 161–170 publications: 477 scientists 171–180 publications: 450 scientists 181–190 publications: 397 scientists 191–200 publications: 343 scientists 201–210 publications: 328 scientists 211–220 publications: 313 scientists 221–230 publications: 283 scientists 231–240 publications: 226 scientists 241–250 publications: 196 scientists 251–260 publications: 201 scientists 261–270 publications: 171 scientists 271–280 publications: 151 scientists 281–290 publications: 139 scientists 291–300 publications: 113 scientists 301–310 publications: 102 scientists 311–320 publications: 100 scientists 321–330 publications: 76 scientists 331–340 publications: 92 scientists 341–350 publications: 85 scientists 351–360 publications: 69 scientists 361–370 publications: 71 scientists 371–380 publications: 63 scientists 381–390 publications: 58 scientists 391–400 publications: 57 scientists 401–410 publications: 43 scientists 411–420 publications: 33 scientists 421–430 publications: 50 scientists 431–440 publications: 41 scientists 441–450 publications: 32 scientists 451–460 publications: 27 scientists 461–470 publications: 28 scientists 471–480 publications: 25 scientists 481–490 publications: 28 scientists 491–500 publications: 20 scientists 501–510 publications: 23 scientists 511–520 publications: 26 scientists 521–530 publications: 17 scientists 531–540 publications: 21 scientists 541–550 publications: 14 scientists 551–560 publications: 16 scientists 561–570 publications: 10 scientists 571–580 publications: 22 scientists 581–590 publications: 9 scientists 591–600 publications: 14 scientists 601–610 publications: 9 scientists 611–620 publications: 11 scientists 621–630 publications: 4 scientists 631–640 publications: 7 scientists 641–650 publications: 5 scientists 651–660 publications: 10 scientists 661–670 publications: 8 scientists 671–680 publications: 8 scientists 681–690 publications: 4 scientists 691–700 publications: 3 scientists 701–704 publications: 4 scientists 705+ publications: 100 scientists
31 publications 705+

This scientist: 176 publications — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 705 publications or more.

Toshiaki A. Furukawa D-index placement in Psychology in 2026

The chart shows the D-index (discipline H-index) distribution of Psychology scientists ranked by Research.com in 2026. The highlighted bar marks where Toshiaki A. Furukawa sits on this spectrum.

30–31 D-Index: 398 scientists 32–33 D-Index: 702 scientists 34–35 D-Index: 671 scientists 36–37 D-Index: 659 scientists 38–39 D-Index: 641 scientists 40–41 D-Index: 671 scientists 42–43 D-Index: 617 scientists 44–45 D-Index: 558 scientists 46–47 D-Index: 495 scientists 48–49 D-Index: 487 scientists 50–51 D-Index: 445 scientists 52–53 D-Index: 390 scientists 54–55 D-Index: 408 scientists 56–57 D-Index: 345 scientists 58–59 D-Index: 325 scientists 60–61 D-Index: 321 scientists 62–63 D-Index: 248 scientists 64–65 D-Index: 290 scientists 66–67 D-Index: 218 scientists 68–69 D-Index: 219 scientists 70–71 D-Index: 215 scientists 72–73 D-Index: 183 scientists 74–75 D-Index: 169 scientists 76–77 D-Index: 132 scientists 78–79 D-Index: 137 scientists 80–81 D-Index: 120 scientists 82–83 D-Index: 112 scientists 84–85 D-Index: 86 scientists 86–87 D-Index: 101 scientists 88–89 D-Index: 83 scientists 90–91 D-Index: 77 scientists 92–93 D-Index: 70 scientists 94–95 D-Index: 78 scientists 96–97 D-Index: 58 scientists 98–99 D-Index: 53 scientists 100–101 D-Index: 57 scientists 102–103 D-Index: 48 scientists 104–105 D-Index: 53 scientists 106–107 D-Index: 46 scientists 108–109 D-Index: 24 scientists 110–111 D-Index: 35 scientists 112–113 D-Index: 27 scientists 114–115 D-Index: 32 scientists 116–117 D-Index: 31 scientists 118–119 D-Index: 22 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 24 scientists 124–125 D-Index: 18 scientists 126–127 D-Index: 11 scientists 128–129 D-Index: 19 scientists 130–131 D-Index: 10 scientists 132–133 D-Index: 16 scientists 134–135 D-Index: 10 scientists 136–137 D-Index: 12 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 5 scientists 142–143 D-Index: 12 scientists 144+ D-Index: 98 scientists
30 D-Index 144+

This scientist: 51 D-Index — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 144 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Psychology in Japan Leader Award
  • 2025 - Research.com Psychology in Japan Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Psychiatry
  • Major depressive disorder

Toshiaki A. Furukawa spends much of his time researching Psychiatry, Depression, Internal medicine, Randomized controlled trial and Quality of life. His Psychiatry research focuses on Alexithymia in particular. His study in Depression is interdisciplinary in nature, drawing from both Mental health, Physical therapy and Alcohol abuse.

His Internal medicine research integrates issues from Venlafaxine, Relapse prevention, CINAHL and Sertraline. His research in Sertraline intersects with topics in Escitalopram, Tolerability, Systematic review, Duloxetine and Mirtazapine. His work deals with themes such as Odds ratio, Clinical trial, Absolute risk reduction, Meta-analysis and Placebo, which intersect with Randomized controlled trial.

His most cited work include:

  • Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis (1246 citations)
  • Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review (658 citations)
  • Cross-cultural validation of the Beck Depression Inventory-II in Japan. (290 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Psychiatry, Depression, Clinical psychology, Internal medicine and Psychometrics. His research links Randomized controlled trial with Psychiatry. His research integrates issues of Cancer, Psychosocial, Anxiety, Hemodialysis and Pediatrics in his study of Depression.

His Clinical psychology research also works with subjects such as

  • Cronbach's alpha that intertwine with fields like Construct validity,
  • Cognition that connect with fields like Degenerative disease, Cognitive psychology and Dementia. His Internal medicine study combines topics in areas such as Antidepressant, Sertraline and Venlafaxine. His Psychometrics research includes themes of Item response theory, Center for Epidemiologic Studies Depression Scale, Major depressive episode and Rating scale.

He most often published in these fields:

  • Psychiatry (52.43%)
  • Depression (29.13%)
  • Clinical psychology (24.27%)

What were the highlights of his more recent work (between 2008-2020)?

  • Psychiatry (52.43%)
  • Clinical psychology (24.27%)
  • Depression (29.13%)

In recent papers he was focusing on the following fields of study:

Psychiatry, Clinical psychology, Depression, Internal medicine and Mental health are his primary areas of study. His Psychiatry research incorporates elements of Odds ratio and Risk factor. His work on Psychometrics as part of general Clinical psychology study is frequently linked to Human sexuality, bridging the gap between disciplines.

Toshiaki A. Furukawa combines subjects such as Cancer, Physical therapy, Severity of illness and Rheumatoid arthritis with his study of Depression. The concepts of his Internal medicine study are interwoven with issues in Mirtazapine and Oncology. Toshiaki A. Furukawa has researched Mental health in several fields, including Alternative medicine, Public health and Comorbidity.

Between 2008 and 2020, his most popular works were:

  • Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis (1246 citations)
  • Depression, inflammation, and pain in patients with rheumatoid arthritis. (143 citations)
  • Systematic review and meta-analysis of cannabis treatment for chronic pain. (140 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Psychiatry
  • Major depressive disorder

Toshiaki A. Furukawa mostly deals with Psychiatry, Quality of life, Internal medicine, Hospital Anxiety and Depression Scale and Physical therapy. His study in Psychiatry is interdisciplinary in nature, drawing from both Odds ratio, Randomized controlled trial, Meta-analysis, Placebo and Disease. His Internal medicine research integrates issues from Venlafaxine, Escitalopram, Duloxetine and Citalopram.

His research investigates the link between Hospital Anxiety and Depression Scale and topics such as Psychological intervention that cross with problems in Clinical psychology. His Physical therapy research is multidisciplinary, incorporating perspectives in Psychosocial, Cross-sectional study, Depression and Anxiety. Toshiaki A. Furukawa is studying Beck Depression Inventory, which is a component of Depression.

Best Publications

  • Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

    Andrea Cipriani;Andrea Cipriani;Toshiaki A Furukawa;Georgia Salanti;John R Geddes

  • Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

    John R Geddes;Stuart M Carney;Christina Davies;Toshiaki A Furukawa

  • Cross-cultural validation of the Beck Depression Inventory-II in Japan

    Masayo Kojima;Toshiaki A Furukawa;Hidekatsu Takahashi;Makoto Kawai

  • Twelve‐month prevalence, severity, and treatment of common mental disorders in communities in Japan: preliminary finding from the World Mental Health Japan Survey 2002–2003

    Norito Kawakami;Tadashi Takeshima;Yutaka Ono;Hidenori Uda

  • Systematic review and meta-analysis of cannabis treatment for chronic pain.

    Eva Martín-Sánchez;Toshiaki A. Furukawa;Julian Taylor;Jose Luis R. Martin

  • Can we individualize the ‘number needed to treat’? An empirical study of summary effect measures in meta-analyses

    Toshiaki A Furukawa;Gordon H Guyatt;Lauren E Griffith

  • Depression, inflammation, and pain in patients with rheumatoid arthritis.

    Masayo Kojima;Toshihisa Kojima;Sadao Suzuki;Takeshi Oguchi

  • Efficacy of cognitive bias modification interventions in anxiety and depressive disorders: a systematic review and network meta-analysis.

    Liviu A Fodor;Raluca Georgescu;Pim Cuijpers;Ştefan Szamoskozi

  • Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous aborters

    Mayumi Sugiura-Ogasawara;Toshiaki A. Furukawa;Yumi Nakano;Shiro Hori

  • Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan

    Tatsuo Akechi;Toru Okuyama;Chiharu Endo;Ryuichi Sagawa

  • Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence

    Norman Sartorius;Thomas C. Baghai;David S. Baldwin;Barbara Barrett

  • Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials

    Corrado Barbui;Toshiaki A. Furukawa;Andrea Cipriani

  • Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials.

    Jose Luis R. Martin;Maria Sainz-Pardo;Toshiaki A. Furukawa;Eva Martin-Sanchez

  • Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis

    Masayo Kojima;Toshihisa Kojima;Naoki Ishiguro;Takeshi Oguchi

  • Alexithymia, Depression and Social Support among Japanese Workers

    Masayo Kojima;Yoshihiro Senda;Teruo Nagaya;Shinkan Tokudome

  • Neuropsychiatric symptoms predict change in quality of life of Alzheimer disease patients: a two-year follow-up study.

    Hiroshi Tatsumi;Shutaro Nakaaki;Katsuyoshi Torii;Yoshihiro Shinagawa

  • Time to recovery of an inception cohort with hitherto untreated unipolar major depressive episodes

    Toshiaki A. Furukawa;Toshinori Kitamura;Kiyohisa Takahashi

  • Early parental separation experiences among patients with bipolar disorder and major depression: a case-control study.

    T.A Furukawa;A Ogura;T Hirai;S Fujihara

  • The differential impact of executive attention dysfunction on episodic memory in obsessive-compulsive disorder patients with checking symptoms vs. those with washing symptoms.

    Ichiro M. Omori;Yoshie Murata;Tomoaki Yamanishi;Shutaro Nakaaki

  • Are all antidepressants really the same? The case of fluoxetine: a systematic review.

    Andrea Cipriani;Corrado Barbui;Paolo Brambilla;Toshiaki A. Furukawa

  • Course of psychological distress and its predictors in advanced non-small cell lung cancer patients.

    Tatsuo Akechi;Toru Okuyama;Nobuya Akizuki;Hideki Azuma

Frequent Co-Authors

Tatsuo Akechi
Tatsuo Akechi Nagoya City University
Toshinori Kitamura
Toshinori Kitamura Kitamura Institute of Mental Health Tokyo
Andrea Cipriani
Andrea Cipriani University of Oxford
Yosuke Uchitomi
Yosuke Uchitomi National Cancer Research Institute, UK
Corrado Barbui
Corrado Barbui University of Verona
Kiyohisa Takahashi
Kiyohisa Takahashi Shiga University of Medical Science
Noboru Iwata
Noboru Iwata Kiryu University
Masaru Mimura
Masaru Mimura Keio University
Yutaka Ono
Yutaka Ono Keio University
Norito Kawakami
Norito Kawakami University of Tokyo

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in psychology can open doors to a range of rewarding careers, including various roles in social work. As a licensed social worker, you will help individuals, families, and communities improve their well-being—often building on a psychology background. However, educational requirements to become a social worker can differ significantly across states.

For example, those interested in becoming a social worker should carefully review the social worker degree requirements in Kansas. Requirements can include specific accredited degrees and supervised fieldwork. Similarly, learning about the social worker education requirements in Kentucky helps prospective students understand regional licensing standards.

Other states, such as Louisiana and Maine, also have unique standards. Students should research the degree needed to be a social worker in Louisiana and the degree needed to be a social worker in Maine before choosing an educational program. Comparing these options helps future professionals choose the best pathway to meet their career goals, either on campus or through accredited online degrees.

Best Scientists Citing Toshiaki A. Furukawa

Trending Scientists

Recently Published Articles